Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?


Coker, R; (2002) Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)? The international journal of tuberculosis and lung disease , 6 (8). pp. 649-50. ISSN 1027-3719

Full text not available from this repository. (Request a copy)
Item Type: Article
Keywords: Antitubercular Agents/*therapeutic use, *Communicable Disease Control/economics, Cost-Benefit Analysis, Costs and Cost Analysis, Human, Tuberculosis, Multidrug-Resistant/*drug therapy
Faculty and Department: Faculty of Public Health and Policy > Dept of Global Health and Development
Research Centre: Antimicrobial Resistance Centre (AMR)
PubMed ID: 12150473
Web of Science ID: 177114800002
URI: http://researchonline.lshtm.ac.uk/id/eprint/17607

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
262Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item